<code id='C0175E1FAF'></code><style id='C0175E1FAF'></style>
    • <acronym id='C0175E1FAF'></acronym>
      <center id='C0175E1FAF'><center id='C0175E1FAF'><tfoot id='C0175E1FAF'></tfoot></center><abbr id='C0175E1FAF'><dir id='C0175E1FAF'><tfoot id='C0175E1FAF'></tfoot><noframes id='C0175E1FAF'>

    • <optgroup id='C0175E1FAF'><strike id='C0175E1FAF'><sup id='C0175E1FAF'></sup></strike><code id='C0175E1FAF'></code></optgroup>
        1. <b id='C0175E1FAF'><label id='C0175E1FAF'><select id='C0175E1FAF'><dt id='C0175E1FAF'><span id='C0175E1FAF'></span></dt></select></label></b><u id='C0175E1FAF'></u>
          <i id='C0175E1FAF'><strike id='C0175E1FAF'><tt id='C0175E1FAF'><pre id='C0175E1FAF'></pre></tt></strike></i>

          entertainment

          entertainment

          author:explore    Page View:18
          Mayo Clinic, in Rochester, Minnesota on
          Photo by KEREM YUCEL/AFP via Getty Images

          SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generative AI partner, the health system announced Monday.

          The health system — known for its cutting-edge research and willingness to partner with tech companies — will give Cerebras millions of dollars to help build technology tools based on Mayo’s trove of de-identified patient data, leaders announced at the J.P. Morgan Healthcare Conference. Mayo and Cerebras did not disclose the dollar amount, but Cerebras said it was a multimillion, multi-year contract.

          advertisement

          With roughly 380 employees, Cerebras builds and sells supercomputers specifically designed for AI applications across several industries — pitting the upstart in direct competition with the market leader Nvidia Corp. Life sciences giants including GSK have used its technology for drug discovery, and it has partnered with a health network in United Arab Emirates, but this is Cerebras’ first AI contract with a U.S. health system. The deal gives Mayo access to Cerebras’ supercomputers as well as a Cerebras team to help develop health-tuned models; Mayo will then own whatever they build.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy
          FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

          PeterMarks,theFDA'stopregulatorofgenetherapies(right),speakswithSTAT'sAdamFeuersteininSanFrancisco.S

          read more
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

          6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

          read more

          Men with early prostate cancer can safely opt out of treatment

          AnMRIscanoftheprostate.MichaelOhliger/UCSFMendiagnosedwithearlyprostatecancercansafelychooseactivemo